Earnings Releases·Nov 4, 2026, 4:20 PM ET

Biote — Third Quarter 2026 Earnings Summary

Total revenue declined 9.6% year-over-year to $43.3 million, driven by a 15.1% drop in procedure revenue offset by 7.3% growth in dietary supplements, while net income fell to $0.6 million from $9.2 million in the prior year.
Gross profit margin contracted to 67.7% from 71.8% due to residual impacts from the January 2026 voluntary recall, which necessitated increased use of lower-margin third-party pellets.
The company maintained its full-year 2026 guidance unchanged, projecting revenue above $175 million and Adjusted EBITDA above $25 million, though management acknowledges growth is progressing more slowly than anticipated.
Cash and cash equivalents decreased to $8.9 million from $24.1 million at year-end 2025, while the company repurchased $7.2 million of Class A common stock and incurred $5.6 million in legal settlement expenses related to the recall.